Administration of an anti-IL-6 antibody decreased IL-6 levels to levels found in control mice and prevented 67% and 60% of the cancer-induced increase in plasma LBP levels and hepatic Lbp expression, respectively, meaning that IL-6 levels are responsible, at least partially, for the increased plasma LBP levels and hepatic Lbp expression. Here, LBP is linked to cancer.